Sunil Patel is Director at LIGAND PHARMACEUTICALS INC (LGND). They have made 13 open-market trades across 4 companies since 2011, most recently 2023-01-30.
CIK 0001503062
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $487K since 2011, against 6 sales. Across 6 scored buys the stock is up 24.0% at ninety days, and 20.5 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 17% | 50% |
| Avg Move | -6.6% | +1.9% | +24.0% |
| Alpha | -4.4% | +0.2% | +20.5% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OABI | BUY | 2022-11-09 | 2022-11-10 | $2.77 | $119K | -2.0% | +28.1% | +34.9% |
| LGND | BUY | 2020-11-02 | 2020-11-04 | $82.52 | $83K | -7.9% | -2.8% | +98.8% |
| LGND | BUY | 2019-08-02 | 2019-08-05 | $95.98 | $96K | +0.3% | -3.8% | +20.6% |
| LGND | SELL | 2018-08-16 | 2018-08-17 | $240.05 | $20.3M | +3.4% | +2.2% | -38.8% |
| OMED | SELL | 2017-10-10 | 2017-10-12 | $4.24 | $5K | -11.1% | +7.7% | -32.1% |
| OMED | SELL | 2017-04-04 | 2017-04-05 | $9.06 | $104K | -55.9% | -58.7% | -59.5% |
| OMED | SELL | 2016-01-06 | 2016-01-08 | $22.28 | $96K | -18.1% | -55.5% | -47.5% |
| LGND | SELL | 2015-03-19 | 2015-03-20 | $74.42 | $342K | -9.9% | -3.4% | -3.4% |
| OMED | SELL | 2015-03-19 | 2015-03-23 | $27.76 | $500K | -32.1% | -0.5% | -0.5% |
| LGND | BUY | 2012-05-23 | 2012-05-24 | $11.39 | $16K | -9.9% | -3.4% | -3.4% |
| LGNDD | BUY | 2011-11-10 | 2011-11-10 | $11.11 | $28K | N/A | N/A | N/A |
| LGND | BUY | 2011-08-10 | 2011-08-11 | $10.74 | $54K | -9.9% | -3.4% | -3.4% |
| LGND | BUY | 2011-02-16 | 2011-02-17 | $9.22 | $92K | -9.9% | -3.4% | -3.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.